Teva Takes Tuznue Trastuzumab Biosimilar In Israel From Prestige
Latest Out-Licensing Deal Signed By Prestige BioPharma
Prestige BioPharma is continuing to put pen to paper on deals to supply and sell its HD201 biosimilar trastuzumab candidate, this time partnering with Israeli giant Teva for local commercialization rights.
You may also be interested in...
Russia’s Pharmapark has added Prestige BioPharma’s HD204 biosimilar bevacizumab product to the firms’ commercialization partnership, two years after kicking off the partnership with trastuzumab.
Saudi firm Tabuk has struck a deal to sell Prestige BioPharma’s Tuznue trastuzumab biosimilar in the MENA region.
Pharma’s latest partnerships focus on Duchenne muscular dystrophy with Precision Biosciences, protein degradation with Seed. Bristol and Schrodinger team in computational drug discovery.